---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-26-000011"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:35:53.511654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbbVie records $744M IPR&D expense in Q1; cuts adjusted EPS guidance by $0.41

## Summary
- Q1 2026 includes $744M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.41.
- Updated Q1 adjusted EPS guidance: $2.56-$2.60 (from $2.97-$3.01, excluding Q1 IPR&D).
- Full-year 2026 adjusted EPS guidance lowered to $13.96-$14.16 (from $14.37-$14.57).
- Company states future IPR&D milestones cannot be reliably forecasted; guidance excludes them beyond Q1.
- Adjusted diluted EPS guidance now includes impact of Q1 expense; prior range excluded it.

## SEC filing metadata
- accession: 0001551152-26-000011
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/0001551152-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/abbv-20260403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-26-000011
- JSON: https://secwatch.observer/filing/0001551152-26-000011.json
- Plain text: https://secwatch.observer/filing/0001551152-26-000011.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported quarter ended March 31, 2026 results: EPS $2.56 - $2.60. Guidance lowered.
  - Period: quarter ended March 31, 2026
  - EPS: $2.56 - $2.60
  - Guidance: lowered
  - Result: guidance update
  source text: AbbVie’s first quarter 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $2.56 - $2.60.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/0001551152-26-000011-index.htm
- Earnings Releases
  AbbVie Inc. reported full-year ended December 31, 2026 results: EPS $13.96 - $14.16. Guidance lowered.
  - Period: full-year ended December 31, 2026
  - EPS: $13.96 - $14.16
  - Guidance: lowered
  - Result: guidance update
  source text: AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $13.96 - $14.16.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/0001551152-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.